Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Moshfiq Abeer (Hull, United Kingdom), Moshfiq Abeer, Thompson Joanne, Cummings Helena, Watkins Karen, Jaymin Morjaria. Does omalizumab attenuate blood eosinophilia at 52 weeks; a single centre observation. Eur Respir J 2015; 46: Suppl. 59, 1016

Member's Comments

No comment yet.

Related content which might interest you: Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016 The role of adherence to inhaled corticosteroids (ICS) in the relationship between blood eosinophilia and asthma control Source: International Congress 2016 – Asthma management in primary care Year: 2016 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Clinical-functional and inflammatory evolution after one year of tracking in patients with asthma according to induced sputum cellularity Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Effect of 1 year treatment with inhaled corticosteroids with electronically assessed adherence on height growth in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013